FDA Approves Botox for Pediatric Patients with Upper Limb SpasticityApprovals, Brain Damage, FDA, FDA/Regulatory, Priority Review, Spine Damage, Supplemental Biologics License Application (sBLA), Upper Limb SpasticityThe U.S. Food and Drug Administration approved Allergan plc’s supplemental biologics application for Botox for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity. Read more June 21, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-06-21 07:30:572019-06-21 13:23:41FDA Approves Botox for Pediatric Patients with Upper Limb Spasticity
